Literature DB >> 5033844

The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver.

M C Kew, R R Varma, D J Sampson, S Sherlock.   

Abstract

The effect of octapressin (2-phenylalanine-8-lysine vasopressin) on renal and intrarenal blood flow was studied in 11 normotensive cirrhotic patients with abnormal renal perfusion. Renal haemodynamic changes were assessed with the (133)Xenon washout technique. Of the six patients given suppressor doses of octapressin intravenously renal blood flow improved in one only. A further three patients responded to the drug in a dose which increased the mean arterial pressure by 5 or more mm Hg. The increase in mean renal blood flow was accompanied by an improvement in renal cortical perfusion. In two patients renal blood flow decreased after the administration of octapressin. These findings, in conjunction with previous reports, suggest that octapressin will only consistently improve renal perfusion in cirrhotic subjects who are hypotensive and in whom the mean arterial blood pressure is raised by the drug, but do not exclude the possibility that octapressin may have a direct renal circulatory effect in some patients.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5033844      PMCID: PMC1412168          DOI: 10.1136/gut.13.4.293

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  HEMODYNAMIC AND RENAL EFFECTS OF OCTAPRESSIN.

Authors:  L D LONGO; J A MORRIS; R W SMITH; R BECK; N S ASSALI
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

2.  THE KIDNEY IN CIRRHOSIS. II. DISORDERS OF RENAL FUNCTION.

Authors:  W P BALDUS; R N FEICHTER; W H SUMMERSKILL; J C HUNT; K G WAKIM
Journal:  Ann Intern Med       Date:  1964-03       Impact factor: 25.391

3.  The effect of the intravenous administration of pitressin on renal function in man.

Authors:  M H MAXWELL; E S BREED
Journal:  J Pharmacol Exp Ther       Date:  1951-10       Impact factor: 4.030

4.  Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man.

Authors:  J N Cohn; F E Tristani; I M Khatri
Journal:  Circulation       Date:  1968-07       Impact factor: 29.690

5.  Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin.

Authors:  E T Schroeder; L Shear; S M Sancetta; G J Gabuzda
Journal:  Am J Med       Date:  1967-12       Impact factor: 4.965

6.  Effects of dopamine on renal function in patients with cirrhosis.

Authors:  D E Barnardo; W P Baldus; F T Maher
Journal:  Gastroenterology       Date:  1970-04       Impact factor: 22.682

Review 7.  Hepatic failure and the kidney.

Authors:  W H Summerskill
Journal:  Gastroenterology       Date:  1966-07       Impact factor: 22.682

8.  Renal vasodilator therapy in the hepatorenal syndrome.

Authors:  J N Cohn; F E Tristani; I M Khatri
Journal:  Med Ann Dist Columbia       Date:  1970-01

9.  Partition coefficient of 133-xenon between various tissues and blood in vivo.

Authors:  A M Andersen; J Ladefoged
Journal:  Scand J Clin Lab Invest       Date:  1967       Impact factor: 1.713

10.  Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion.

Authors:  F E Tristani; J N Cohn
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  7 in total

1.  Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis.

Authors:  K Lenz; H Hörtnagl; W Druml; G Grimm; A Laggner; B Schneeweisz; G Kleinberger
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

Review 2.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 3.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 4.  [Hepatorenal syndrome in decompensated cirrhosis : A special form of acute renal failure].

Authors:  K Lenz; R Buder; G Lohr; P Piringer; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-30       Impact factor: 0.840

Review 5.  Renal changes in cirrhosis.

Authors:  M Kew
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

6.  Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis.

Authors:  K Lenz; W Druml; G Kleinberger; H Hörtnagl; A Laggner; B Schneeweiss; E Deutsch
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

Review 7.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.